Medtronic plc (4MDT.TI)

73,75 -4,55 (-5,81%) In data: 09:09AM CEST. Mercato aperto.

Medtronic plc

20 On Hatch
Lower Hatch Street
Dublin 2
Ireland
353 1 438 1700
https://www.medtronic.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 95.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Geoffrey Straub Martha	Chairman of the Board & CEO	1,68M	N/D	1970
Ms. Karen L. Parkhill	Executive VP & CFO	929,09k	N/D	1965
Mr. Sean M. Salmon	Executive VP & President of Cardiovascular Portfolio	843,63k	392,06k	1965
Mr. Robert J. W. ten Hoedt	Executive VP & President of Global Regions	1,16M	89,9k	1960
Mr. Mark Ploof	Senior Vice President of Global Operations and Business Services	N/D	N/D	N/D
Ms. Jennifer M. Kirk	Senior VP, Global Controller & Chief Accounting Officer	N/D	N/D	1975
Dr. Kenneth E. Washington Ph.D.	Senior VP and Chief Technology & Innovation Officer	N/D	N/D	1960
Dr. Laura Mauri M.D., M.Sc.	Senior VP and Chief Scientific & Medical Officer	N/D	N/D	N/D
Mr. Ryan Weispfenning	VP & Head of Investor Relations	N/D	N/D	N/D
Mr. Ivan K. Fong	Executive VP, General Counsel & Secretary	922,85k	N/D	1961

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Medtronic plc al 1 giugno 2024 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 6; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.